As shown in Table 3, patients with ocular candidiasis were significantly younger, had more commonly a history of renal disease [53.8% (7/13) vs 26.5% (41/155), p = 0.05] and a higher median Pitt score at presentation of the candidemia [3 vs 1 p = 0.01]. Fungemia causing ocular candidiasis was more frequently persistent [61.5% (8/13) vs 26.5% (41/155), p = 0.02], was produced by C. albicans [76.9% (10/13) vs 47.1% (73/155), p = 0.04], spread to other organs [38.5% (5/13) vs 9.7% (15/155), p = 0.01], and conditioned more need for hemodialysis [30.8% (4/13) vs 1.9% (3/155), p = 0.001]. As for antifungal treatment, patients with ocular candidiasis more commonly received an adequate antifungal therapy within the first 48 hours [100 (13/13) vs 67.7% (105/155), p = 0.01], and had a longer length of antifungal therapy (mean days 22.2 vs 39.6, p = 0.047). No further differences were found between the groups regarding demographics, risk factors, and management of candidemia. In the multivariate analysis (Table 4), the independent risk conditions for eye involvement were need for hemodialysis after candidemia (OR, 19.4; 95% CI, 1.7–218.4) and involvement of organs other than the eye (OR, 5.4; 95% CI, 1.1–25.7).